Share This

Related Topics News -

     
 Title only   |   Print    Next page > 
     
信達生物第一季總收入逾24億人民幣 保持40%以上增長

2025-05-01T  
信達生物第三代肺癌靶向藥物奧壹新獲准上市

2025-04-27T  
《大行》美銀上調信達生物今明兩年銷售預測 目標價上調至61.1元

2025-04-25T  
《大行》大摩:若中美關稅戰能顯著降溫 料中資科網、消費品和醫療板塊造好 但建議短期保持耐心及採平衡策略

2025-04-24T  
《大行》摩通列出MSCI中國指數各板塊成份股今年以來獲上調盈測較多的股份(表)

2025-04-15T  
《大行》瑞銀上調信達生物目標價至66.3元 重申「買入」

2025-04-14T  
美國國會報告:中國生物技術進步威脅美國主導地位

2025-04-08T  
港股通小米集團淨流入25.35億港元

2025-04-07T  
《大行》匯豐研究:信達生物上財年首達non-IFRS收支平衡 升目標價至60元

2025-04-07T  
《大行》麥格理升信達生物目標價至38元 料今年轉盈

2025-04-07T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.